Transplantation: Graft Cell Promotion of Rejection
移植:移植细胞促进排斥反应
基本信息
- 批准号:6745731
- 负责人:
- 金额:$ 41.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-04-01 至 2006-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant):
Our Iongterm objective is to understand the interactions of the innate and adaptive immune response in the pathogenesis of graft rejection. Recent work from our laboratory investigating cardiac transplants in lymphocyte deficient recipients has characterized a robust innate (antigen independent) immune response following transplantation including the identification of a candidate gene, interleukin 6 (IL-6) that is produced by graft tissue, is markedly upregulated by ischemia, and is necessary for robust graft rejection. Interestingly, data from our murine model shows that IL-6 deficiency in the transplant recipient does NOT prolong graft survival, whereas IL-6 deficiency in the donor graft tissue significantly prolongs graft survival more than 3 fold. Although IL-6 is produced within the graft, major increases in IL-6 receptor (both IL-6Ralpha and gp130) occur in the lymph node, but not within the graft. Based on these observations, we postulate that the targets for IL-6 dependent effects could be lymph node cells, suggesting that IL-6 functions at a distance by endocrine like mechanisms. Consistent with this possibility, we also detect high levels of IL-6 in the serum in the IL-6 deficient recipient group, but not in the IL-6 deficient graft group. Relevant to this paradigm, recent studies have established that IL-6 can block immune suppression by regulatory T cells (Treg). Thus, we will investigate links between graft produced IL-6 and functions of Treg cells following transplantation. Most previous studies investigating rejection have focused on the immune response versus the graft. In contrast, our proposal will focus on the proinflammatory response induced by the graft tissue that we postulate is a crucial component in promoting the adaptive rejection response. Thus, an innate response generated by the graft tri.q.qers an adaptive alloimmune response. Our hypothesis is that IL-6 is produced by the graft by antigen-independent innate immune mechanisms and enhances the adaptive alloimmune response that mediates rejection by inhibiting regulatory T cell function. Aim 1 will investigate the production and regulation of IL-6 by graft tissue following transplantation. Aim 2 will identify cells in the peripheral lymphoid tissue with IL-6 dependent activation. And, Aim 3 will determine the mechanisms of IL-6 dependent activation of alloimmune responses by modulation of regulatory T cells.
描述(由申请人提供):
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Linn Perkins其他文献
David Linn Perkins的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Linn Perkins', 18)}}的其他基金
PERIPHERAL T CELL TOLERANCE INDUCED BY SUPERANTIGENS
超抗原诱导的外周 T 细胞耐受
- 批准号:
3455881 - 财政年份:1991
- 资助金额:
$ 41.18万 - 项目类别:
PERIPHERAL T-CELL TOLERANCE INDUCED BY SUPERANTIGENS
超抗原诱导的外周 T 细胞耐受
- 批准号:
2066495 - 财政年份:1991
- 资助金额:
$ 41.18万 - 项目类别:
PERIPHERAL T CELL TOLERANCE INDUCED BY SUPERANTIGENS
超抗原诱导的外周 T 细胞耐受
- 批准号:
3455879 - 财政年份:1991
- 资助金额:
$ 41.18万 - 项目类别:
PERIPHERAL T-CELL TOLERANCE INDUCED BY SUPERANTIGENS
超抗原诱导的外周 T 细胞耐受
- 批准号:
2066496 - 财政年份:1991
- 资助金额:
$ 41.18万 - 项目类别:
相似海外基金
Safety and efficacy of Belatacept in heart transplantation
贝拉西普在心脏移植中的安全性和有效性
- 批准号:
10622240 - 财政年份:2023
- 资助金额:
$ 41.18万 - 项目类别:
Targeted immune therapies in heart transplantation
心脏移植中的靶向免疫治疗
- 批准号:
10573846 - 财政年份:2023
- 资助金额:
$ 41.18万 - 项目类别:
Developing Machine Learning Models for Decision Support and Allocation Optimization in Heart Transplantation
开发用于心脏移植决策支持和分配优化的机器学习模型
- 批准号:
10735348 - 财政年份:2023
- 资助金额:
$ 41.18万 - 项目类别:
Dissecting the Role of Donor CCR2- Macrophages During Acute Cellular Rejection After Heart Transplantation
剖析供体 CCR2-巨噬细胞在心脏移植后急性细胞排斥过程中的作用
- 批准号:
10449753 - 财政年份:2022
- 资助金额:
$ 41.18万 - 项目类别:
Immunoregulatory Mechanisms of IL-33 in Heart Transplantation
IL-33在心脏移植中的免疫调节机制
- 批准号:
10680570 - 财政年份:2022
- 资助金额:
$ 41.18万 - 项目类别:
Dissecting the Role of Donor CCR2- Macrophages During Acute Cellular Rejection After Heart Transplantation
剖析供体 CCR2-巨噬细胞在心脏移植后急性细胞排斥过程中的作用
- 批准号:
10597230 - 财政年份:2022
- 资助金额:
$ 41.18万 - 项目类别:
Narrowing the gap between supply and demand in heart transplantation
缩小心脏移植供需差距
- 批准号:
10396268 - 财政年份:2022
- 资助金额:
$ 41.18万 - 项目类别:
Multiparametric Cardiac Positron Emission Tomography for Cardiac Allograft Vasculopathy Surveillance After Heart Transplantation: MARINER Trial
多参数心脏正电子发射断层扫描用于心脏移植后心脏同种异体移植血管病变监测:MARINER 试验
- 批准号:
469893 - 财政年份:2022
- 资助金额:
$ 41.18万 - 项目类别:
Operating Grants
Immunogenetic Profiling for Risk of Primary Graft Dysfunction after Heart Transplantation
心脏移植后原发性移植物功能障碍风险的免疫遗传学分析
- 批准号:
10391731 - 财政年份:2021
- 资助金额:
$ 41.18万 - 项目类别:
Immunogenetic Profiling for Risk of Primary Graft Dysfunction after Heart Transplantation
心脏移植后原发性移植物功能障碍风险的免疫遗传学分析
- 批准号:
10515335 - 财政年份:2021
- 资助金额:
$ 41.18万 - 项目类别:














{{item.name}}会员




